Received Mar 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
the limited protection of PPSV23 against mucosal disease could have made the patient susceptible to the development of IPD; This literature marketed report as received from the authors of a published literature article, and refers to a 66-year-old patient of unknown gender. The patient had a history of tobacco smoking, chronic obstructive pulmonary disease, and poorly controlled diabetes. On an unknown date in 2019 (reported as 3 years prior), the patient was vaccinated with pneumococcal Vaccine, Polyvalent (23-valent) for prophylaxis (strength, dose, route of administration, anatomical location, lot number, and expiration date were not reported). It was reported, the patient had presence of multiple comorbidities and the limited protection of PPSV23 against mucosal disease could have made the patient development of invasive pneumococcal disease (IPD) (Vaccination failure). The event vaccination failure was considered to be related to pneumococcal Vaccine, Polyvalent (23-valent).
Chronic obstructive pulmonary disease; Diabetes mellitus poor control; Tobacco user